Miami, Florida — February 6, 2026 CaseBioscience® has announced the launch of CaseCryo® CTG DMSO and CaseStor® HSS Hypothermic Storage Solution at Advanced Therapies Week (ATW) 2026, unveiling clinically engineered preservation platforms designed to enhance cell viability, functional performance, and manufacturing consistency across advanced therapy workflows. The introduction reflects rising industry focus on preservation science as a determinant of therapeutic potency, particularly as cell and gene therapies scale from experimental programs into commercial manufacturing environments. By addressing both cryogenic freezing and hypothermic transport conditions, the technologies aim to strengthen end-to-end cellular handling infrastructure.
Science Significance
The launch highlights scientific progress in preservation biology, where maintaining post-thaw cellular functionality is as critical as survival rates. CaseCryo® CTG DMSO is engineered to optimize cryogenic protection at structural and metabolic levels, reducing intracellular stress, osmotic damage, and oxidative injury during freeze-thaw cycles. Modern cell therapies—including CAR-T, stem cell, and regenerative products—require preservation environments that protect not only membrane integrity but also gene expression and differentiation potential. Complementing this, CaseStor® HSS enables controlled hypothermic storage, stabilizing cells and tissues in reduced metabolic states during transport and short-term holding. Together, the solutions represent an integrated approach to safeguarding therapeutic cell fitness across manufacturing and clinical delivery timelines.
Regulatory Significance
From a compliance perspective, the platforms are designed for regulated clinical use. CaseCryo® CTG DMSO is produced under ISO 13485:2016–certified quality systems at an FDA-registered facility, reinforcing its classification as a clinical-grade bioprocess material. Drug Master Files (DMFs) are being prepared for both products to support investigational and commercial therapy submissions. In advanced therapy manufacturing, preservation media are treated as critical raw materials, subject to sterility validation, traceability controls, and change-management oversight under GMP frameworks. Incorporating regulatory principles derived from assisted reproductive technology workflows further strengthens process reproducibility and quality governance.
Business Significance
Advertisement
Commercially, the launch expands CaseBioscience’s footprint within the rapidly growing advanced therapies supply chain. As cell therapy developers scale manufacturing, demand is increasing for standardized, regulator-ready preservation inputs that can integrate seamlessly into validated production systems. The new solutions complement the company’s broader portfolio, which includes washing, dissociation, and embryo culture media. Showcasing the technologies at ATW 2026 enables engagement with biopharma manufacturers, CDMOs, and translational institutes, reinforcing CaseBioscience’s positioning as a strategic innovation partner in the cellular medicine ecosystem.
Patients’ Significance
Although preservation technologies operate behind the scenes, their impact on patients is direct and profound. Cell therapies rely on living cells delivered at defined potency thresholds, meaning preservation failures can compromise therapeutic outcomes. Technologies like CaseCryo® CTG DMSO aim to ensure consistent post-thaw viability, stable dosing, and predictable clinical performance. Improved hypothermic storage also supports broader geographic treatment access by extending safe transport windows. These advancements ultimately contribute to safer infusions, improved remission durability, and enhanced treatment reliability for patients receiving cellular therapies.
Policy Significance
The emergence of advanced preservation platforms intersects with evolving regulatory and policy frameworks governing cell and gene therapies. Health authorities are placing increasing emphasis on cold chain validation, raw material qualification, and vein-to-vein traceability. Standardized preservation solutions may streamline global regulatory harmonization and accelerate multinational clinical trial deployment. Additionally, AI-assisted cryoprotectant discovery research highlighted by the company signals future policy considerations around digital integration in biologics manufacturing and validation of algorithm-supported material design.
As advanced therapies transition toward mainstream clinical adoption, preservation science is becoming foundational infrastructure rather than a supporting function. The launch of CaseCryo® CTG DMSO and CaseStor® HSS reflects a shift toward clinically engineered preservation ecosystems designed for regulatory rigor, manufacturing scalability, and therapeutic reliability. By strengthening the biological stability of living medicines from production through infusion, next-generation biopreservation technologies are poised to play a decisive role in the future success of cell therapy.
Source: CaseBioscience Inc. press release
